Is immunotherapy effective for recurrent bladder cancer?

Hello,

Welcome to icliniq.com.

I understand your concern.

I understand how incredibly stressful it must be to face a recurrence after everything you have already been through. Let us go over your treatment options and what to expect next in the case of recurrent bladder cancer, particularly if it is non-muscle-invasive bladder cancer (NMIBC), which appears to be the likely diagnosis again. When bladder cancer recurs, and if the new lesions are still confined to the bladder lining, it is considered non-muscle-invasive. While recurrence is unfortunately common, bladder cancer has one of the highest recurrence rates among cancers. The encouraging news is that there are well-established treatment options, and many patients continue to do well for years after recurrence.

Intravesical Bacillus Calmette–Guérin (BCG) therapy remains the gold standard for high-risk NMIBC, including recurrent cases. BCG is administered directly into the bladder through a catheter and is not a form of systemic chemotherapy. It can still be effective during a second course, especially if the initial response was favorable. However, if the cancer is BCG-unresponsive or returns after adequate BCG therapy, alternative treatments must be considered.

Common side effects of BCG therapy include local bladder irritation, such as urinary frequency, urgency, burning, or mild bleeding. Systemic symptoms like fatigue and flu-like reactions are also common. Rare but serious side effects may involve high fever or systemic infection. If your previous BCG treatment was manageable, you may tolerate it again, although side effects can sometimes be more pronounced during a second course, particularly due to increased bladder sensitivity.

If the cancer does not respond to BCG or progresses, systemic immunotherapy may be the next step. Intravenous immune checkpoint inhibitors such as Atezolizumab, Nivolumab, or Pembrolizumab are often used in these cases. These medications work by stimulating the body’s immune system to recognize and attack cancer cells. Immunotherapy may be considered for patients with high-risk, BCG-unresponsive NMIBC who are not suitable candidates for surgery, or when the cancer becomes muscle-invasive or metastatic. Side effects are generally milder than those associated with chemotherapy and may include fatigue, rash, diarrhea, or, in rare cases, immune-related inflammation of organs.

Radical cystectomy, or surgical removal of the bladder, may become necessary in certain high-risk situations. This includes cases where the cancer invades the bladder muscle, when there is persistent or progressive carcinoma in situ (CIS), or when the disease is unresponsive to BCG therapy. While this is a major surgical procedure, it can be curative in select patients. Surgical reconstruction options such as the creation of a neobladder or a urostomy are available, and many patients go on to maintain a good quality of life, especially when the surgery is performed at a high-volume, experienced center.

I hope you are satisfied with my answer. For further queries, you can consult me at iCliniq.

Thank you.